Business Context and Reporting Period
This Form 8-K Current Report was filed by InMed Pharmaceuticals Inc. on October 16, 2025, covering events occurring on October 14 and October 15, 2025. The Company is a British Columbia corporation with its principal executive offices in Vancouver, Canada, and its common shares trade on The Nasdaq Stock Market under the symbol "INM". The filing primarily addresses changes to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size to six members.
- Director Appointment: Mr. John Bathery was appointed as a director effective October 14, 2025. His term will expire immediately before the 2025 Annual General Meeting.
- Director Retirement: Mr. Bryan Baldasare notified the Company on October 15, 2025, that he will not stand for re-election at the 2025 Annual General Meeting due to increasing professional obligations.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The Company confirmed there is no disagreement between Mr. Baldasare and the Company regarding operations, policies, or practices. Mr. Bathery's compensation includes an annual retainer of US$50,000, with potential additional amounts for committee service. No related party transactions or family relationships requiring disclosure were identified.
Investor Verification Checklist
- Verify the specific committee assignments for the newly appointed director, Mr. John Bathery, as these were not determined at the time of filing.
- Confirm the composition of the Board following the 2025 Annual General Meeting to see if Mr. Baldasare's departure is finalized and if Mr. Bathery is re-elected.
- Review the press release (Exhibit 99.1) for any additional context regarding the strategic rationale for the Board changes.